CAS: 1310693-92-5; N-Hydroxy-4-((2-Methyl-1,2,3,4-Tetrahydro-5H-Pyrido[4,3-B]Indol-5-yl)Methyl)Benzamide Hydrochloride
该化合物是一种选择性的,强大的抑制乙酰酶6(HDAC6)的强效抑制剂,其IC50值为~15 nM. 它表明HDAC6相对于其他HDAC异形具有高度的特性,使其成为研究HDAC6代管细胞过程的宝贵工具.该化合物在研究中被广泛使用,以调查HDAC6在蛋白聚合,...
- 英文名称N-Hydroxy-4-((2-Methyl-1,2,3,4-Tetrahydro-5H-Pyrido[4,3-B]Indol-5-yl)Methyl)Benzamide Hydrochloride
- 中文名称N-羟基-4-[(1,2,3,4-四氢-2-甲基-5H-吡啶并[4,3-B]吲哚-5-基)甲基]苯甲酰胺盐酸盐
- IUPAC名称N-hydroxy-4-((2-methyl-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)methyl)benzamide hydrochloride
- 其它别名4-((2-Methyl-3,4-Dihydro-1H-Pyrido(4,3-B)Indol-5-yl)Methyl)Benzenecarbohydroxamic Acid Hydrochloride; N-Hydroxy-4-[(2-Methyl-3,4-Dihydro-1H-Pyrido[4,3-B]Indol-5-yl)Methyl]Benzamide; Hydrochloride; Tsa Hcl; Unii-Uhcm2Ayjvx
- CAS编号1310693-92-5
- MFCD编号:MFCD20488052
- FDA UNII编号:UHCM2AYJVX
- 分子式:C20H22ClN3O2分子量:371.87
- 产品CID: 471518
- 同类组份化合物CAS1310693-92-5 (HCl)1252003-15-8 (free base)1239034-70-8 (TFA)
- 产品分类医药中间体 → 吡啶类化合物
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2912110000-甲醛
2912210000-苯甲醛
2921199090-其他无环单胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Wang M, Gao M, Miller KD, Sledge GW, Zheng QH. [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1569-74. doi: 10.1016/j.bmcl.2011.12.136. Epub 2012 Jan 10. doi: 10.1158/1535-7163.MCT-14-0548. Epub 2014 Dec 12. doi: 10.1186/s12935-014-0090-z. eCollection 2014.
4: Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther. 2011 Jun 1;11(11):938-46. Epub 2011 Jun 1.
5: Dolman ME, Westerhout EM, Hamdi M, Schellens JH, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. J Pharm Biomed Anal. 2015 Mar 25;107:403-8. doi: 10.1016/j.jpba.2015.01.026. Epub 2015 Jan 19. doi: 10.1124/jpet.115.229393. Epub 2015 Nov 24.
合成参考文献
参考文献:10.1186/s13148-021-01037-1
摘要:Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson J, Richard S, Raynal NJ-. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Clinical Epigenetics. 2021 Mar 10;13(1):54. doi: 10.1186/s13148-021-01037-1.
📝 需求与反馈
尽可能描述清楚需求与问题信息
